TC Biopharm (Holdings) Plc (TCBPW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TC Biopharm (Holdings) Plc (TCBPW) Healthcare & Pipeline Overview

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical firm advancing an allogeneic gamma delta T cell platform for immunotherapy. Its pipeline includes OmnImmune for acute myeloid leukemia, ImmuniStim for COVID-19, and TCB009 for gastrointestinal cancers, alongside preclinical candidates for solid tumors.

What Is the Investment Thesis for TCBPW?

TC Biopharm (Holdings) Plc presents an investment thesis centered on its innovative allogeneic gamma delta T cell platform, which holds potential in developing 'off-the-shelf' immunotherapies for various diseases. The company's pipeline, including OmnImmune for acute myeloid leukemia and TCB009 for gastrointestinal cancers, targets significant unmet medical needs within oncology, representing substantial market opportunities upon successful development and commercialization. The ImmuniStim program for COVID-19 also diversifies its therapeutic focus. As a clinical-stage biopharmaceutical company, its value drivers are intrinsically linked to successful progression through clinical trials, positive data readouts, and subsequent regulatory approvals. The innovative nature of gamma-delta T cell technology in immunotherapy positions it as a potential differentiator in a competitive landscape. However, the thesis acknowledges significant risks inherent in drug development, including lengthy timelines, high costs, and the uncertainty of clinical success and regulatory clearance. Future funding requirements will be critical for pipeline advancement, making the company's cash runway and ability to secure capital key considerations for investors.

Based on FMP financials and quantitative analysis

TCBPW Key Highlights

Operates as a clinical-stage biopharmaceutical company focused on immunotherapy development.

• Utilizes an innovative allogeneic gamma delta T cell platform for therapeutic applications.
• Pipeline includes OmnImmune, an unmodified cell therapy for acute myeloid leukemia, currently in clinical trials.
• Developing ImmuniStim for COVID-19 and TCB009 for gastrointestinal tract cancers.
• Preclinical programs TCB005 and TCB006 target various solid tumors using GD-T CAR candidates.

Who Are TCBPW's Competitors?

TCBPW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TCBPW's Key Strengths?

Innovative allogeneic gamma delta T cell platform with 'off-the-shelf' potential.

• Diverse clinical and preclinical pipeline targeting multiple high-need indications (AML, GI cancers, solid tumors, COVID-19).
• Established in 2013, indicating a foundational period of research and development.
• Focus on genetically unmodified and CAR-modified gamma delta T cells offers versatility.

What Are TCBPW's Weaknesses?

Clinical-stage company with no commercialized products, leading to no current revenue generation.

• Significant capital requirements for ongoing clinical trials and research and development.
• High regulatory hurdles and lengthy development timelines inherent in biopharmaceutical drug development.
• Reliance on successful clinical trial outcomes, which are inherently uncertain.

What Could Drive TCBPW Stock Higher?

TCBPW catalyst: Release of clinical trial data for OmnImmune in acute myeloid leukemia, which could validate the efficacy and safety of the allogeneic gamma delta T cell platform.

• Progression of ImmuniStim through clinical development for COVID-19, potentially demonstrating the platform's versatility beyond oncology.
• Initiation of clinical trials for TCB009 in gastrointestinal tract cancers, marking a significant step for this specific oncology program.
• Continued advancement of preclinical candidates TCB005 and TCB006 towards Investigational New Drug (IND) application, signaling pipeline expansion into solid tumors.
• Securing additional financing or strategic partnerships to fund ongoing research and development activities and clinical programs.

What Are the Key Risks for TCBPW?

Financial-distress signal — its Altman Z-Score of -14.71 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for OmnImmune, ImmuniStim, or TCB009 to meet primary endpoints, which could significantly impact the company's valuation and future prospects.
• Significant capital requirements and the need to secure future funding to sustain operations and advance the pipeline, posing a risk to cash runway.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities, which can extend development timelines and increase costs.
• Intense competition within the immunotherapy and cell therapy space from larger, more established pharmaceutical companies and other biotech firms.
• Challenges in manufacturing and scaling up production of allogeneic cell therapies to meet future commercial demand, if approved.

What Are the Growth Opportunities for TCBPW?

• **Advancement of OmnImmune for Acute Myeloid Leukemia (AML):** The successful progression and eventual commercialization of OmnImmune, an unmodified cell therapy for AML, represents a significant growth opportunity. AML is a rapidly progressing cancer of the blood and bone marrow, with an estimated global market size for AML treatments projected to reach several billion dollars annually. Current treatments often have significant side effects and limited efficacy in relapsed/refractory settings. OmnImmune's allogeneic nature could offer a novel, more accessible treatment option, potentially capturing a substantial share of this market by providing an 'off-the-shelf' solution that addresses the urgent need for new therapies in this aggressive disease.
• **Development of TCB009 for Gastrointestinal Tract Cancers:** TC Biopharm's TCB009 program, targeting gastrointestinal tract cancers, represents another substantial growth avenue. Cancers of the gastrointestinal tract, including colorectal, gastric, and pancreatic cancers, collectively represent a massive global disease burden and a multi-billion dollar market. These cancers are often diagnosed at advanced stages, leading to poor prognoses and a high demand for innovative therapies. TCB009's development could address critical unmet needs in these indications, offering a new therapeutic modality. Successful clinical trials and regulatory approval would open access to a broad patient population within a large and underserved oncology market.
• **Expansion into Solid Tumors with Preclinical Candidates (TCB005, TCB006):** The company's preclinical pipeline, specifically TCB005 and TCB006, which are allogeneic co-stimulatory GD-T CAR candidates for various solid tumors, offers long-term growth potential. Solid tumors represent the vast majority of cancer diagnoses and a market worth hundreds of billions of dollars globally. Developing effective cell therapies for solid tumors has been challenging due to the complex tumor microenvironment. If these preclinical candidates demonstrate efficacy and safety in subsequent clinical development, they could unlock access to an enormous market segment, positioning TC Biopharm as a key player in a highly lucrative and impactful area of oncology.
• **Leveraging ImmuniStim for Viral Diseases, including COVID-19:** The development of ImmuniStim, an unmodified cell therapy for COVID-19, provides a growth opportunity by diversifying the company's therapeutic focus beyond oncology into infectious diseases. While the immediate pandemic phase of COVID-19 may evolve, the need for robust antiviral and immune-modulating therapies for severe viral infections remains. The global market for antiviral drugs is substantial and continuously growing. Successful development and potential broader application of ImmuniStim's mechanism of action to other severe viral infections could establish a new revenue stream and demonstrate the versatility of the gamma delta T cell platform, expanding the company's addressable market.
• **Strategic Partnerships and Licensing Agreements:** As a clinical-stage company, securing strategic partnerships or licensing agreements with larger pharmaceutical companies represents a critical growth opportunity. Such collaborations can provide significant non-dilutive funding, access to advanced manufacturing capabilities, and established global commercialization infrastructure. The innovative nature of TC Biopharm's allogeneic gamma delta T cell platform, particularly its 'off-the-shelf' potential, makes it an attractive target for larger players seeking to expand their immunotherapy portfolios. These partnerships could accelerate the development and market penetration of TC Biopharm's pipeline assets, validating its technology and providing capital for further research and development.

What Threats Does TCBPW Face?

• Clinical trial failures or unexpected safety concerns could halt development of key pipeline assets.
• Intense competition from larger pharmaceutical companies and other biotech firms developing cell therapies.
• Challenges in securing sufficient future funding to sustain research and development activities.
• Regulatory delays or unfavorable decisions impacting approval timelines and market access.
• Patent challenges or the emergence of superior competing technologies.

What Are TCBPW's Competitive Advantages?

• Proprietary allogeneic gamma delta T cell platform, which aims to provide 'off-the-shelf' cell therapies.
• Intellectual property surrounding its specific cell therapy candidates and manufacturing processes.
• Clinical trial progress and data, which establish validation and regulatory pathways for its pipeline assets.
• Expertise in gamma delta T cell biology and immunotherapy development, built since its founding in 2013.
• Potential first-mover advantage or differentiated profile for specific indications within the allogeneic cell therapy space.

What Does TCBPW Do?

TC Biopharm (Holdings) Plc, established in 2013 and headquartered in Motherwell, United Kingdom, is a biopharmaceutical firm operating in the clinical trial phase. The company is dedicated to the advancement of innovative immunotherapy treatments, with its core scientific approach centered on an allogeneic gamma delta T cell platform. This platform represents a significant area of focus in the evolving field of cellular immunotherapies, aiming to leverage the innate immune system for therapeutic benefit. The company's development portfolio is diverse, addressing both hematological malignancies and solid tumors, as well as viral diseases. Key candidates include OmnImmune, an unmodified cell therapy specifically designed to treat acute myeloid leukemia, which is currently undergoing clinical evaluation. Another significant asset in development is ImmuniStim, also an unmodified cell therapy, which is being developed to address COVID-19, highlighting the company's broader scope beyond oncology. Furthermore, TC Biopharm is progressing TCB009, a therapeutic candidate specifically targeting gastrointestinal tract cancers, an area with substantial unmet medical need. Beyond these clinical-stage programs, the company maintains a robust preclinical pipeline. This includes TCB005 and TCB006, which are allogeneic co-stimulatory GD-T CAR (Chimeric Antigen Receptor) candidates. These preclinical programs are strategically positioned to address various types of solid tumors, representing the next generation of the company's therapeutic innovation. TC Biopharm's focus on allogeneic therapies aims to offer 'off-the-shelf' treatments, potentially reducing manufacturing complexity and costs compared to autologous approaches, thereby broadening patient access.

What Products and Services Does TCBPW Offer?

• Develop allogeneic gamma delta T cell immunotherapies for various diseases.
• Focus on 'off-the-shelf' cell therapies, aiming for broader accessibility and scalability.
• Conduct clinical trials for OmnImmune, an unmodified cell therapy targeting acute myeloid leukemia (AML).
• Develop ImmuniStim, an unmodified cell therapy, for the treatment of COVID-19.
• Advance TCB009, a therapeutic candidate specifically designed for gastrointestinal tract cancers.
• Engage in preclinical research for next-generation allogeneic co-stimulatory GD-T CAR candidates (TCB005, TCB006) for solid tumors.
• Operate as a biopharmaceutical firm in the clinical trial phase, headquartered in Motherwell, UK.

How Does TCBPW Make Money?

• Primarily a research and development-focused biopharmaceutical company, currently in the clinical trial phase.
• Future revenue generation is contingent upon successful clinical development, regulatory approvals, and commercialization of its therapeutic candidates.
• Potential revenue streams include product sales of approved therapies, milestone payments from strategic partnerships, and licensing agreements.
• Funding for operations is typically secured through equity financing, grants, and potentially future debt financing or collaborations.
• Focuses on developing proprietary cell therapy platforms and intellectual property for long-term value creation.

What Industry Does TCBPW Operate In?

TC Biopharm (Holdings) Plc operates within the highly dynamic and research-intensive biotechnology industry, specifically focusing on immunotherapy. The broader healthcare sector is experiencing significant growth driven by an aging global population, increasing prevalence of chronic diseases, and continuous advancements in medical science. Within biotechnology, cell and gene therapies, particularly immunotherapies, represent a rapidly expanding segment with substantial investment and innovation. TC Biopharm's niche in allogeneic gamma delta T cell therapies positions it within a competitive landscape that includes larger pharmaceutical companies and other biotech firms developing CAR-T, TCR, and NK cell therapies. Its 'off-the-shelf' allogeneic approach aims to differentiate it by potentially offering advantages in scalability and accessibility compared to patient-specific autologous treatments, addressing a key market trend towards more accessible advanced therapies.

Who Are TCBPW's Key Customers?

• Ultimately, patients suffering from acute myeloid leukemia, gastrointestinal tract cancers, solid tumors, and severe viral infections like COVID-19.
• Healthcare providers (hospitals, oncologists, infectious disease specialists) who would prescribe and administer approved therapies.
• Regulatory bodies (e.g., FDA, EMA) whose approval is necessary for market access.
• Potential pharmaceutical partners for co-development, licensing, or commercialization agreements.
• Clinical trial participants who volunteer for studies of investigational therapies.

Company Profile

TC Biopharm (Holdings) Plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Motherwell, GB. The company is led by CEO Bryan Leland Kobel.

How TC Biopharm (Holdings) Plc Is Valued

Relative to its peer group, TCBPW's quantitative score of 38/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -66.1%, showing how much profit it generates from its asset base. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations.

TC Biopharm (Holdings) Plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.71 places it in the distress zone, a signal of elevated financial risk.

TCBPW Financials

TCBPW Latest News

No recent news available for TCBPW.

TCBPW Analyst Consensus

TCBPW MoonshotScore

Common Questions About TCBPW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources